-

An Invitation to Innovaderm’s 5th Breakfast Event, This Year’s Focus is on Alopecia Areata (AA)

SAN DIEGO--(BUSINESS WIRE)--Celebrating our tradition, Innovaderm Research is pleased to announce its upcoming 5th annual Breakfast Event at the American Academy of Dermatology (AAD) in San Diego on Saturday, March 9, 2024, at 7:00 AM PST. Let’s mark this 5th anniversary milestone together!

This year, the event will focus on the world of Alopecia Areata (AA). We are honored to have Dr. Brett King and Dr. Natasha Mesinkovska, two globally esteemed Key Opinion Leaders in the field, who will be imparting their valuable insights and expertise. They will be sharing thoughts on “Clinical Evaluations and Current Treatments for AA” and “Experimental and Future Treatments of AA” respectively. This presents a unique opportunity to gain knowledge from leading experts in the field.

The Breakfast Event will serve as a platform to engage in insightful discussions and network with industry professionals, clinicians, and peers in dermatology clinical research.

If you plan to attend AAD in San Diego, we highly recommend reserving your place at our Breakfast Event without further ado. Please be aware that availability is limited, and early registration is advised to secure your spot.

Clinical research events like this one are crucial for advancing medical knowledge and improving patient care.

We look forward to welcoming all attendees to this exciting event.

Register here: https://chloe.insightly.services/rl/BMEXXZI5NZG1

Innovaderm Research Inc.
Innovaderm Research Inc. is a global, full-service CRO specialized in therapeutic dermatology. Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials. Its mission is to drive innovative research initiatives and offer new therapies for patients living with skin disease.

Contacts

For more information:
Valerie Coveney
Communications Specialist
Innovaderm Research Inc.
vcoveney@innovaderm.com

Industry:

Innovaderm Research Inc.

Release Versions
EnglishSpanish (Summary)GermanFrenchItalian (Summary)Dutch (Summary)

Contacts

For more information:
Valerie Coveney
Communications Specialist
Innovaderm Research Inc.
vcoveney@innovaderm.com

More News From Innovaderm Research Inc.

Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression

MONTREAL--(BUSINESS WIRE)--Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our g...

Indero Celebrates 25 Years and Looks to the Future of Clinical Research

MONTREAL--(BUSINESS WIRE)--Indero, the niche CRO formerly known as Innovaderm, is celebrating 25 years of advancing clinical research. From its roots as a dermatology site in Montreal, Indero has grown into a global organization with capabilities in more than 30 countries across 4 continents and has earned a reputation for delivering expert, efficient trials in dermatology and, more recently, rheumatology. Indero was founded as Innovaderm in 2000, starting as a clinical site and now a global CR...

Innovaderm Research Rebrands as Indero, a Dual-Focus CRO

MONTREAL--(BUSINESS WIRE)--Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity reinforces the company’s dual focus on rheumatology and dermatology and recognizes the close synergy between these fields. Innovaderm has over 25 years of clinical research experience within dermatology, and recognizes that many inflammatory and autoimmune conditions manifest across both the skin and the musculosk...
Back to Newsroom